| Title: | Steep dose-response relationship for stage I non-small cell lung cancer using hypo-fractionated high-dose irradiation by real-time tumor-tracking radiotherapy (RTRT) |
| Authors: | Onimaru, Rikiya Browse this author →KAKEN DB |
| Fujino, Masaharu Browse this author |
| Yamazaki, Koichi Browse this author |
| Onodera, Yuya Browse this author |
| Taguchi, Hiroshi Browse this author |
| Katoh, Norio Browse this author →KAKEN DB |
| Hommura, Fumihiro Browse this author |
| Oizumi, Satoshi Browse this author →KAKEN DB |
| Nishimura, Masaharu Browse this author →KAKEN DB |
| Shirato, Hiroki Browse this author →KAKEN DB |
| Keywords: | real-time tumor-tracking radiotherapy |
| stereotactic radiotherapy |
| lung cancer |
| Issue Date: | 1-Feb-2008 |
| Publisher: | Elsevier |
| Journal Title: | International Journal of Radiation Oncology*Biology*Physics |
| Volume: | 70 |
| Issue: | 2 |
| Start Page: | 374 |
| End Page: | 381 |
| Publisher DOI: | 10.1016/j.ijrobp.2007.06.043 |
| PMID: | 18029106 |
| Abstract: | Purpose: To investigate the clinical outcomes of patients with pathologically proven, peripherally located, stage I non-small cell lung cancer (NSCLC) who received stereotactic body radiotherapy (SBRT) using real-time tumor tracking radiotherapy (RTRT) during the developmental period.
Materials and Methods: Forty-one patients were admitted (T1, 25; T2, 16) from February 2000 to June 2005. A 5 mm lanning target volume (PTV) margin was added to the clinical target volume determined with computed tomography at the end of expiratory phase. The gating window ranged from ± 2 to 3 mm. The dose fractionation schedule was 40 or 48 Gy in 4 fractions within 7 days. The dose was prescribed at the center of the PTV, giving more than an 80% dose at the PTV periphery.
Results: For 28 patients treated with 48 Gy in 4 fractions, the overall actuarial survival (OAS) at 3 years was 82% for stage IA and 32% for stage IB. For patients treated with 40Gy/4Fr/1wk, OAS at 3 years was 50% for stage IA and 0% for stage IB. There was a significant difference in local control between 40 and 48 Gy in stage IB (p=0.0015) but not in stage IA (p=0.5811). No serious radiation morbidity was observed in either dose schedule.
Conclusion: Forty-eight Gy in 4 fractions in one week was found to be a safe and effective treatment for peripherally located, stage IA NSCLC. A steep dose-response curve between 40 and 48 Gy using a daily dose of 12 Gy delivered in one week was identified for stage IB NSCLC in SBRT using RTRT. |
| Relation: | http://www.sciencedirect.com/science/journal/03603016 |
| Type: | article (author version) |
| URI: | http://hdl.handle.net/2115/33040 |
| Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
